宜明昂科-B盘中涨超10% MC-003/IMM72临床试验申请获国家药监局受理

新浪港股
24 Apr
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  宜明昂科-B(01541)盘中涨超10%,截至发稿,股价上涨4.06%,现报6.66港元,成交额2048.60万港元。

  宜明昂科本月初公布,集团IMC-003/IMM72治疗肺动脉高压(PAH)的临床试验申请已获中国国家药监局受理。IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型融合蛋白,具有更高的活性及品质。国元国际此前指出,公司前阶段因为退出港股通,股价回调,目前价值严重低估,建议积极关注。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10